cytoplasmic endogenous regulator of oxidative phosphorylation 1Genealiases: []
Q-omics provides the consensus-scored CEROX1 profile across patient tissues and cancer cell-line models. CEROX1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CEROX1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CEROX1 RNA expression shows 18,915 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, THCA, and GBM as cancer lineages where CEROX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEROX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEROX1 survival associations across molecular data types. CEROX1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEROX1 RNA expression–survival associations across cancer types. High CEROX1 expression shows unfavorable associations in PRAD, ACC and BRCA, but favorable associations in LGG, KICH and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CEROX1 RNA expression.
This table summarizes CEROX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEROX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEROX1 shows lower tumor expression in BLCA and BRCA and higher tumor expression in THCA, KIRP, CHOL and LIHC. The THCA box plot shows higher CEROX1 RNA expression in tumor versus normal tissue (log2 FC = +1.985, t-test p < 0.001).
This table shows molecular features associated with CEROX1 in patient tissues and cancer cell lines. In patient samples, CEROX1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
